ABCL — Abcellera Biologics Inc
In 2026 Q2, 3 of the 140 tracked hedge funds reported a position in Abcellera Biologics Inc (ABCL), worth $8.44M combined. Over the quarter 2 opened or added, 2 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Renaissance | $7.78M | 0.01% | -34.4% |
| Caxton Associates | $521.07K | 0.00% | NEW |
| IMC | $135.06K | 0.00% | NEW |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.